Picture of Gilead Sciences logo

GILD Gilead Sciences Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapContrarian

Annual cashflow statement for Gilead Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line5,364896,2014,5665,613
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items5,2728,4512,7605,7182,964
Unusual Items
Other Non-Cash Items
Changes in Working Capital-798-1,638489-1,763-2,302
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Other Operating Cash Flow
Cash from Operating Activities9,1448,16811,3849,0728,006
Capital Expenditures-825-650-579-728-585
Purchase of Fixed Assets
Other Investing Cash Flow Items-6,992-13,965-2,552-1,738-1,680
Acquisition of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-7,817-14,615-3,131-2,466-2,265
Financing Cash Flow Items-122-138-145-173-278
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-7,634770-8,877-6,469-5,125
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-6,309-5,634-65974673